Treatment of nausea and vomiting related to anti-cancerous multiple combination chemotherapy: results of two controlled studies.
Two controlled double-blind studies were carried out successively on a cancerous out-patient population receiving multiple combination chemotherapy at successive treatment courses to show the anti-emetic efficiency of metopimazine compared to a placebo. The patient was taken as his own control and the treatment order was randomly selected. The first trial--consisting of sixty-seven patients, showed a weak statistically significant difference (0.05 less than p less than 0.10) between metopimazine at doses of 30 mg/day or 15 mg/day and a placebo. The second trial--comparing a higher dose of metopimazine (45 mg/day) among one hundred and sixteen patients, showed a highly statistically significant therapeutic advantage over a placebo (0.001 less than p less than 0.01).